# Todd M. Bauer

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/todd-m-bauer/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,297 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 63 |
| i10-index | 187 |
| Last Known Institution | Sarah Cannon |
| OpenAlex ID | https://openalex.org/A5037195922 |
| ORCID iD | https://orcid.org/0000-0002-3078-5043 |
| Works | 531 |

## Researcher papers

- [First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/first-line-lorlatinib-or-crizotinib-in-advanced-i-alk-i-positive-lung-cancer/)
- [Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)](https://scholariq.org/papers/safety-and-antitumor-activity-of-the-multitargeted-pan-trk-ros1-and-alk/)
- [Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors](https://scholariq.org/papers/activation-of-met-via-diverse-exon-14-splicing-alterations-occurs-in-multiple/)
- [Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study](https://scholariq.org/papers/lorlatinib-in-patients-with-alk-positive-non-small-cell-lung-cancer-results-from/)
- [Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-altered-thyroid-cancers/)
- [Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study](https://scholariq.org/papers/rovalpituzumab-tesirine-a-dll3-targeted-antibody-drug-conjugate-in-recurrent/)
- [<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/i-alk-i-resistance-mutations-and-efficacy-of-lorlatinib-in-advanced-anaplastic/)
- [Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial](https://scholariq.org/papers/lorlatinib-in-advanced-ros1-positive-non-small-cell-lung-cancer-a-multicentre/)
- [Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study](https://scholariq.org/papers/safety-and-activity-of-mirvetuximab-soravtansine-imgn853-a-folate-receptor-alpha/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer-related Molecular Pathways](https://scholariq.org/topics/cancer-related-molecular-pathways/)

## Researcher university

- [Sarah Cannon](https://scholariq.org/institutions/sarah-cannon/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.